Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.150449 http://scihub22266oqcxt.onion/10.1172/jci.insight.150449 34237028!8410018!34237028     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34237028&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       JCI+Insight 2021 ; 6 (16): ? Nephropedia Template TP {{tp|p=34237028|t=2021. Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration |pdf=|usr=}}{{34237028}} gab.com Text Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=34237028 #FOAvip Some studies suggest that recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity upon SARS-CoV-2 infection. We completed serological assays using samples collected from health care workers to identify antibody types associated with SARS-CoV-2 protection and COVID-19 symptom duration. Rare SARS-CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly reduced in individuals with higher common betacoronavirus (betaCoV) antibody titers. Since antibody titers decline over time after CCV infections, individuals in our cohort with higher betaCoV antibody titers were more likely recently infected with common betaCoVs compared with individuals with lower antibody titers. Therefore, our data suggest that recent betaCoV infections potentially limit the duration of symptoms following SARS-CoV-2 infections through mechanisms that do not involve cross-reactive antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses elicited by recent common betaCoV infections transiently reduce symptom duration following SARS-CoV-2 infections. Twit Text FOAVip Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=34237028 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34237028 #FOAvip English Wikipedia <ref>{{Cite pmid|34237028}}</ref> Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration #MMPMID34237028 Gouma S; Weirick ME; Bolton MJ; Arevalo CP; Goodwin EC; Anderson EM; McAllister CM; Christensen SR; Dunbar D; Fiore D; Brock A; Weaver J; Millar J; DerOhannessian S; Unit TUCP; Frank I; Rader DJ; Wherry EJ; Hensley SE JCI Insight 2021[Aug]; 6 (16): ? PMID34237028show ga Some studies suggest that recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity upon SARS-CoV-2 infection. We completed serological assays using samples collected from health care workers to identify antibody types associated with SARS-CoV-2 protection and COVID-19 symptom duration. Rare SARS-CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly reduced in individuals with higher common betacoronavirus (betaCoV) antibody titers. Since antibody titers decline over time after CCV infections, individuals in our cohort with higher betaCoV antibody titers were more likely recently infected with common betaCoVs compared with individuals with lower antibody titers. Therefore, our data suggest that recent betaCoV infections potentially limit the duration of symptoms following SARS-CoV-2 infections through mechanisms that do not involve cross-reactive antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses elicited by recent common betaCoV infections transiently reduce symptom duration following SARS-CoV-2 infections. |*Health Personnel[MESH] |Adult[MESH] |Antibodies, Viral/*blood[MESH] |Betacoronavirus/*immunology[MESH] |COVID-19/*immunology[MESH] |Cross Reactions[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/*immunology[MESH]Health care worker seromonitoring reveals complex relationships betwee(epmc).pdf DeepDyve Pubget Overpricing